182 results
To assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary artery lesions compared to the Xience coronary stent…
This research will have as aim to look at progression or decrease of vascular calcification in dialysis population with use of different phosphate binders. There is a possibility that differect phosphate binders bind vitamin K in a different way in…
To determine in all-comers patients undergoing PCI under standardised treatment (including the BioMatrix family of drug-eluting stents and bivalirudin), whether treatment with 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor…
The main objective of this study is to assess the effect of an acute cardiovascular event on the local and the systemic inflammatory state in humans with AMI as well as the reversibility of these effects after 3 months.
To determine if ticagrelor at treatment steady state will be associated to an improved microvascular function as compared to prasugrel in revascularized STEMI patients.
To evaluate the safety and effectiveness of Orsiro for the treatment of subjects with up to 2 de novo atherosclerotic coronary artery lesions.
To prevent vessel damage of the radial artery by using the Cordis Railway sheathless guiding catheter system.
Study goal is to compare the performance of the Absorb bioresorbable scaffold with a metallic drug eltuting stent in the STEMI patient.
The Lipid-rich Plaque Study will be performed in patients undergoing IVUS-NIRS imaging (the index procedure) in whom a TVC catheter will be purchased and used for routine clinical indications. The study will test the ability of multi-vessel NIRS…
The primary objective of the FAME 3 Trial is to demonstrate that FFR-guided PCI is noninferior to coronary artery bypass graft surgery in patients with multivessel CAD.
Primary Objective: The aim of the study is to show that STEMI patients who are pre-treated with crushed ticagrelor and paracetamol have a higher level of platelet inhibition after primary PCI than patients pre-treated with crushed ticagrelor who are…
The primary objective of this randomized trial is to reduce the HbA1c levels by 10% through exercise training with or without oral anti-diabetic medication in patients with coronary artery disease (PCI or CABG in stable CAD, or post STEMI and post…
The hypothesis of the FAME II trial is that FFR-guided PCI (with DES) plus optimal medical treatment is superior to optimal medical treatment alone. The overall purpose of the FAME II study is to compare the clinical outcomes, safety and cost-…
To assess whether the iFR is non-inferior to FFR when used to guide treamtent of coronary stenoses with PCI
The purpose of the trial is to show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in patients with STE-ACS, with an onset of symptoms of >20 minutes and <12 hours,…
Incidence of type 2 diabetes mellitus and cardiovascular disease in familial combined hyperlipidemia
To determine: 1) the incidence of type 2 diabetes mellitus in FCHL patients, normolipidemic relatives and their spouses2) the incidence of cardiovascular disease in FCHL patients, normolipidemic relatives and their spouses3) the prevalence of CESD…
To compare the diagnostic value of CTA versus the standard work-up in terms of identifying patients with severe coronary artery disease (requiring revascularization), as well as the ability to safely discharge patients without coronary artery…
1) identifying new predictors of ST, in particular of late and very late ST and drug eluting stent thrombosis2) to observe clinical outcome after an episode of a ST
The study objective is to assess the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) compared to the Resolute IntegrityTM Drug-Eluting Stent in patients with single, de novo coronary artery lesions.
To test the hypothesis that 6 months DAPT after second generation DES implantation in STEMI is not inferior to 12 months DAPT in terms of clinical outcomes (composite endpoint of all-cause mortality, any MI, any revascularization, stroke and major…